{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:51Z","timestamp":1793814051090,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"DOI":"10.7759\/cureus.85813","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:52:35Z","timestamp":1749707555000},"source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Interlinked Pathophysiology and Integrated Management Approach"],"prefix":"10.7759","author":[{"given":"Carlos Alejandro","family":"Arragan Lezama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Joel","family":"Jaramillo Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alejandro","family":"Armas Eguiz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena Sof\u00eda","family":"Solares Ovando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Cesar","family":"Minera Villagr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya Jhoana","family":"Males Caiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241272639","article-title":"Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases","volume":"52","author":"Chen L","year":"2024","unstructured":"Chen L, Zuo Y, He M, Duo L, Tang W. Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases. J Int Med Res. 2024, 52:03000605241272639. 10.1177\/03000605241272639","journal-title":"J Int Med Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review","volume":"151","author":"Claudel SE","year":"2025","unstructured":"Claudel SE, Verma A. Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review. Circulation. 2025, 151:716-32. 10.1161\/CIRCULATIONAHA.124.071079","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2024.10.012","article-title":"Cardiovascular-kidney-metabolic syndrome: an integrative review","volume":"87","author":"Kittelson KS","year":"2024","unstructured":"Kittelson KS, Junior AG, Fillmore N, da Silva Gomes R. Cardiovascular-kidney-metabolic syndrome: an integrative review. Prog Cardiovasc Dis. 2024, 87:26-36. 10.1016\/j.pcad.2024.10.012","journal-title":"Prog Cardiovasc Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02352-6","article-title":"Association between the triglyceride glucose-body mass index and future cardiovascular disease risk in a population with cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide prospective cohort study","volume":"23","author":"Li W","year":"2024","unstructured":"Li W, Shen C, Kong W, et al.. Association between the triglyceride glucose-body mass index and future cardiovascular disease risk in a population with cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide prospective cohort study. Cardiovasc Diabetol. 2024, 23:292. 10.1186\/s12933-024-02352-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00837-x","article-title":"Post-translational modifications in kidney diseases and associated cardiovascular risk","volume":"20","author":"Noels H","year":"2024","unstructured":"Noels H, Jankowski V, Schunk SJ, Vanholder R, Kalim S, Jankowski J. Post-translational modifications in kidney diseases and associated cardiovascular risk. Nat Rev Nephrol. 2024, 20:495-512. 10.1038\/s41581-024-00837-x","journal-title":"Nat Rev Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000361","article-title":"From cardiorenal syndrome to chronic cardiovascular and kidney disorder: a conceptual transition","volume":"19","author":"Zoccali C","year":"2024","unstructured":"Zoccali C, Mallamaci F, Halimi JM, et al.. From cardiorenal syndrome to chronic cardiovascular and kidney disorder: a conceptual transition. Clin J Am Soc Nephrol. 2024, 19:813-20. 10.2215\/CJN.0000000000000361","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami K","year":"2024","unstructured":"Sawami K, Tanaka A, Node K. Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives. Cardiovasc Diabetol. 2024, 23:410. 10.1186\/s12933-024-02500-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1874","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease","volume":"177","author":"Yen FS","year":"2024","unstructured":"Yen FS, Hwu CM, Liu JS, Wu YL, Chong K, Hsu CC. Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease. Ann Intern Med. 2024, 177:693-700. 10.7326\/M23-1874","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1366","article-title":"Causal links between renal function and cardiac structure, function, and disease risk","volume":"19","author":"Zhou X","year":"2024","unstructured":"Zhou X, Ruan W, Zhao L, et al.. Causal links between renal function and cardiac structure, function, and disease risk. Glob Heart. 2024, 19:83. 10.5334\/gh.1366","journal-title":"Glob Heart"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2022.02.010","article-title":"Commentary: Risk stratification in\u00a0infective endocarditis: the emerging role of the liver-heart-kidney axis","volume":"167","author":"Amabile A","year":"2024","unstructured":"Amabile A, Geirsson A. Commentary: Risk stratification in\u00a0infective endocarditis: the emerging role of the liver-heart-kidney axis. J Thorac Cardiovasc Surg. 2024, 167:141-2. 10.1016\/j.jtcvs.2022.02.010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13649","article-title":"Association of metabolic syndrome and chronic kidney disease","volume":"25","author":"Scurt FG","year":"2024","unstructured":"Scurt FG, Ganz MJ, Herzog C, Bose K, Mertens PR, Chatzikyrkou C. Association of metabolic syndrome and chronic kidney disease. Obes Rev. 2024, 25:e13649. 10.1111\/obr.13649","journal-title":"Obes Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02971-y","article-title":"Assessment of cardio-renal-hepatic function in patients with valvular heart disease: a multi-biomarker approach-the cardio-renal-hepatic score","volume":"21","author":"Lv J","year":"2023","unstructured":"Lv J, Zhang B, Ye Y, et al.. Assessment of cardio-renal-hepatic function in patients with valvular heart disease: a multi-biomarker approach-the cardio-renal-hepatic score. BMC Med. 2023, 21:257. 10.1186\/s12916-023-02971-y","journal-title":"BMC Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13030590","article-title":"From metabolic syndrome to cardio-kidney-metabolic syndrome in the SIMETAP study: prevalence rates of metabolic syndrome and its independent associations with cardio-renal-metabolic disorders other than its defining criteria","volume":"13","author":"Ruiz-Garc\u00eda A","year":"2025","unstructured":"Ruiz-Garc\u00eda A, Arranz-Mart\u00ednez E, Serrano-Cumplido A, Cinza-Sanjurjo S, Escobar-Cervantes C, Polo-Garc\u00eda J, Pallar\u00e9s-Carratal\u00e1 V. From metabolic syndrome to cardio-kidney-metabolic syndrome in the SIMETAP study: prevalence rates of metabolic syndrome and its independent associations with cardio-renal-metabolic disorders other than its defining criteria. Biomedicines. 2025, 13:590. 10.3390\/biomedicines13030590","journal-title":"Biomedicines"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12642","article-title":"Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation","volume":"46","author":"Mikolasevic I","year":"2016","unstructured":"Mikolasevic I, Orlic L, Hrstic I, Milic S. Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation. Hepatol Res. 2016, 46:841-52. 10.1111\/hepr.12642","journal-title":"Hepatol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/a-2266-1503","article-title":"The pathophysiological associations between obesity, NAFLD, and atherosclerotic cardiovascular diseases","volume":"56","author":"Li M","year":"2024","unstructured":"Li M, Cui M, Li G, Liu Y, Xu Y, Eftekhar SP, Ala M. The pathophysiological associations between obesity, NAFLD, and atherosclerotic cardiovascular diseases. Horm Metab Res. 2024, 56:683-96. 10.1055\/a-2266-1503","journal-title":"Horm Metab Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo S","year":"2010","unstructured":"Mottillo S, Filion KB, Genest J, et al.. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010, 56:1113-32. 10.1016\/j.jacc.2010.05.034","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107210","article-title":"Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction","volume":"204","author":"Nasrallah D","year":"2024","unstructured":"Nasrallah D, Abdelhamid A, Tluli O, Al-Haneedi Y, Dakik H, Eid AH. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction. Pharmacol Res. 2024, 204:107210. 10.1016\/j.phrs.2024.107210","journal-title":"Pharmacol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082833","article-title":"Cardiovascular-kidney-metabolic syndrome: a new paradigm in clinical medicine or going back to basics?","volume":"14","author":"Mutruc V","year":"2025","unstructured":"Mutruc V, Bologa C, \u0218orodoc V, et al.. Cardiovascular-kidney-metabolic syndrome: a new paradigm in clinical medicine or going back to basics?. J Clin Med. 2025, 14:2833. 10.3390\/jcm14082833","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-024-00381-6","article-title":"ACE inhibitors and angiotensin receptor blockers for the primary and secondary prevention of cardiovascular outcomes: recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation","volume":"13","author":"Sobhy M","year":"2024","unstructured":"Sobhy M, Eletriby A, Ragy H, et al.. ACE inhibitors and angiotensin receptor blockers for the primary and secondary prevention of cardiovascular outcomes: recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation. Cardiol Ther. 2024, 13:707-36. 10.1007\/s40119-024-00381-6","journal-title":"Cardiol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis N","year":"2025","unstructured":"Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025, 15:213. 10.3390\/biom15020213","journal-title":"Biomolecules"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15485","article-title":"Inter-relationships between cardiovascular, renal and metabolic diseases: underlying evidence and implications for integrated interdisciplinary care and management","volume":"26","author":"Vora J","year":"2024","unstructured":"Vora J, Cherney D, Kosiborod MN, et al.. Inter-relationships between cardiovascular, renal and metabolic diseases: underlying evidence and implications for integrated interdisciplinary care and management. Diabetes Obes Metab. 2024, 26:1567-81. 10.1111\/dom.15485","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada T","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, et al.. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021, 20:14. 10.1186\/s12933-020-01197-z","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022, 145:437-47. 10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v14.i6.329","article-title":"Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"14","author":"Singh AK","year":"2022","unstructured":"Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol. 2022, 14:329-42. 10.4330\/wjc.v14.i6.329","journal-title":"World J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093211","article-title":"Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: a narrative review","volume":"13","author":"Li HY","year":"2021","unstructured":"Li HY, Zhou DD, Gan RY, et al.. Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: a narrative review. Nutrients. 2021, 13:3211. 10.3390\/nu13093211","journal-title":"Nutrients"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12746","article-title":"Hepatoprotective and therapeutic effects of resveratrol: a focus on anti-inflammatory and antioxidative activities","volume":"36","author":"Chupradit S","year":"2022","unstructured":"Chupradit S, Bokov D, Zamanian MY, Heidari M, Hakimizadeh E. Hepatoprotective and therapeutic effects of resveratrol: a focus on anti-inflammatory and antioxidative activities. Fundam Clin Pharmacol. 2022, 36:468-85. 10.1111\/fcp.12746","journal-title":"Fundam Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202303_31558","article-title":"Novel therapeutic approaches based on the pathological role of gut dysbiosis on the link between nonalcoholic fatty liver disease and insulin resistance","volume":"27","author":"Bellucci E","year":"2023","unstructured":"Bellucci E, Chiereghin F, Pacifici F, et al.. Novel therapeutic approaches based on the pathological role of gut dysbiosis on the link between nonalcoholic fatty liver disease and insulin resistance. Eur Rev Med Pharmacol Sci. 2023, 27:1921-44. 10.26355\/eurrev_202303_31558","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention","volume":"9","author":"Tacke F","year":"2021","unstructured":"Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med. 2021, 9:729. 10.21037\/atm-20-4354","journal-title":"Ann Transl Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen SE","year":"2023","unstructured":"Nissen SE, Menon V, Nicholls SJ, et al.. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023, 330:131-40. 10.1001\/jama.2023.9696","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-023-00605-5","article-title":"The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines","volume":"23","author":"Alcocer LA","year":"2023","unstructured":"Alcocer LA, Bryce A, De Padua Brasil D, Lara J, Cortes JM, Quesada D, Rodriguez P. The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines. Am J Cardiovasc Drugs. 2023, 23:663-82. 10.1007\/s40256-023-00605-5","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1101068","article-title":"Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review","volume":"14","author":"Alshahrani S","year":"2023","unstructured":"Alshahrani S. Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review. Front Pharmacol. 2023, 14:1101068. 10.3389\/fphar.2023.1101068","journal-title":"Front Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul U","year":"2019","unstructured":"Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019, 18:80. 10.1186\/s12933-019-0884-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1517174","article-title":"Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders","volume":"16","author":"Cheng M","year":"2025","unstructured":"Cheng M, Ding F, Li L, et al.. Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders. Front Pharmacol. 2025, 16:1517174. 10.3389\/fphar.2025.1517174","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2112945","article-title":"Colesevelam-a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia","volume":"23","author":"Esan O","year":"2022","unstructured":"Esan O, Viljoen A, Wierzbicki AS. Colesevelam-a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. Expert Opin Pharmacother. 2022, 23:1363-70. 10.1080\/14656566.2022.2112945","journal-title":"Expert Opin Pharmacother"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/endocrines1020009","article-title":"PDE5 inhibitors in type 2 diabetes cardiovascular complications","volume":"1","author":"Barbagallo F","year":"2020","unstructured":"Barbagallo F, Campolo F, Franceschini E, et al.. PDE5 inhibitors in type 2 diabetes cardiovascular complications. Endocrines. 2020, 1:90-101. 10.3390\/endocrines1020009","journal-title":"Endocrines"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030373","article-title":"Fighting oxidative stress with sulfur: hydrogen sulfide in the renal and cardiovascular systems","volume":"10","author":"Scammahorn JJ","year":"2021","unstructured":"Scammahorn JJ, Nguyen IT, Bos EM, Van Goor H, Joles JA. Fighting oxidative stress with sulfur: hydrogen sulfide in the renal and cardiovascular systems. Antioxidants (Basel). 2021, 10:373. 10.3390\/antiox10030373","journal-title":"Antioxidants (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377283-cardiovascular-renal-hepatic-metabolic-syndrome-interlinked-pathophysiology-and-integrated-management-approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:52:35Z","timestamp":1749707555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377283-cardiovascular-renal-hepatic-metabolic-syndrome-interlinked-pathophysiology-and-integrated-management-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.85813","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}